Fully Licensed Blueberries Medical Corp. (CSE: BBM) is Perfectly Positioned for Rapid Growth Potential…Yet Remains Significantly Undervalued

The next high upside cannabis company poised for rapid growth is one you most likely haven’t yet heard of.

This is a company with a unique combination of:

  1. An exceptional business plan for international success…
  2. Production facilities in the world’s most optimal location for cannabis growth…
  3. A tremendous advantage of extremely low production costs…
  4. Existing sales and distribution relationships already in place…
  5. And a world-class leadership team with proprietary expertise in critical areas.

Yet in spite of this powerful combination of advantages, the company’s shares appear to be undervalued in comparison to others in the space.

Blueberries Medical Corp. (CSE: BBM) is shaping up to be the single highest-upside cannabis play of 2019 thanks to its current valuation.

Blueberries Medical Corp. (CSE: BBM) is committed to becoming a leading international supplier of medicinal quality cannabis oil extracts, grown and processed to the highest quality standards.

Of course, the most important part of the Blueberries Medical Corp. story is like the old refrain about real estate: location, location, location.

Blueberries Medical Corp. (CSE: BBM) has chosen Colombia as its base of operations due to the company’s excellent climatic and economic conditions.

And as one of the early players in the Colombian cannabis space, Blueberries Medical Corp. is perfectly positioned to take advantage of the low-cost advantages that come with Colombian production in addition to the Company´s extensive cultivation, product development and marketing expertise.

Colombia: The World’s Most Ideal Location for Cultivating Cannabis

Since legalizing medicinal marijuana in 2015, Colombia is developing one of the most comprehensive medicinal Cannabis market in all of Latin America.

Thanks to lower production costs – along with ideal growing conditions and a massive addressable market – Colombia has the ability to become a leading worldwide supplier of medicinal cannabis.

Keep in mind – the reality in Colombia today is far different than the fictionalized Colombia portrayed in movies and television series over 20 years ago.

Today’s Colombia is a strong, rapidly-growing nation that has delivered average GDP growth of 3.36% over the last six years.i

Between 2012 and 2014, Colombia managed to cut its poverty rate by 50% — with more than 6 million people leaving poverty.ii

Colombia has one of the world’s lowest production costs for cannabis and is currently responsible for 44% of the global quota of medicinal cannabis production, which is forecasted to grow from $11 billion to $56 billion by 2025.iv

Cannabis growers in Colombia can cultivate their product for a fraction of the cost paid by growers in Canada or the United States where those companies use warehouses, high-powered sun lamps and climate control.

This exceptionally low production cost gives Blueberries Medical Corp. (CSE: BBM) a significant advantage over others in the cannabis space.

The Company is one of the very first publicly traded producers in Colombia and the recent history with similar producers suggest high upside potential for early investors…

Other Colombian Producers Show that Blueberries Medical Corp. (CSE: BBM) Has Potential for Significant Growth in Valuation

At the moment, there are only two other publicly-traded companies with primary medicinal-grade cannabis production operations in Colombia: Khiron Life Sciences Corp. (TSXV: KHRN) and PharmaCielo Ltd. (TSXV: PCLO).

A quick look at the valuations for these companies shows the extraordinary potential for Blueberries Medical Corp. (CSE: BBM).

Khiron Life Sciences went public in May 2018 and currently trades for just under $3 per share and has a market cap of more than $210 million.

PharmaCielo Ltd. went public in January 2019 and now is trading just over $8 per share and has a market cap of more than $812 million.

Khiron Life Sciences, in fact, recently announced a $20 million bought deal equity financing agreement with Canaccord Genuity Corp. and BMO Capital Markets as co-lead underwriters. This agreement is reflective of the strong interest in the Colombian cannabis markets at this time.

Blueberries Medical Corp. (CSE: BBM) is Fully Licensed to Produce in Colombia

Blueberries Medical Corp. (CSE: BBM) is rapidly emerging as a potential market leader in the Colombian cannabis space thanks in large part to its low production costs and highly experienced management team.

In addition, the Company has all of the required licenses to grow, extract, process and commercialize cannabis derivatives in Colombia and abroad.

These licenses – granted by the Ministries of Justice and Health – are necessary to produce cannabis with low and high contents of THC and commercialize, manufacture and export derived products.

Ideally-Located Production Facilities and Outstanding Scalability

Blueberries Medical Corp’s current production facility is located in one of the safest areas in Colombia and is just 64 kilometers from the El Dorado International Airport.

This region boasts a number of logistical advantages, including a wide availability of a trained and productive labor force. In addition, 70% of all Colombian cut flower production comes from the Bogota Savannah region.

The current Blueberries facility has 3 hectares of available land, as well as easy access, water availability and flat land and is just 60 minutes away from Bogota in an agricultural area. These are critical attributes that give Blueberries advantages over its peers.

With production facilities in place with existing infrastructure including greenhouses and irrigation system, Blueberries Medical Corp. (CSE: BBM) is already moving forward with production.

The company has multiple farms – and 18 hectares of land – with the option to acquire or lease an additional 100 acres. This gives the company outstanding scalability – all in the world’s premier region for growing cut flowers.

The Blueberries Medical Corp. (CSE: BBM) Cost Advantage

As mentioned earlier, Colombia’s ideal location allows companies like Blueberries Medical Corp. (CSE: BBM) to cultivate their product for a fraction of the cost paid by growers in Canada or the United States.

Blueberries Medical Corp. (CSE: BBM) enjoys multiple cost savings from operating in Colombia with dramatically lower:

  • Infrastructure capital expenditures – with no artificial climate control systems needed
  • Labor costs – significant savings in this area provide critical advantage
  • Electricity costs – with no cooling or high-intensity lighting required 
  • Water costs – with no municipal water supply needed.

This significantly lower cost of production has enabled Blueberries Medical Corp. (CSE: BBM) to develop a unique – and highly efficient – cultivation model.

This cultivation model will be scaled by including third party Contract Growers in order to increase the production available without the need for future capital investment.

134 Exclusive Cannabis Strains and Key Distribution Agreements Position Blueberries Medical Corp. (CSE: BBM) as a Fast-Moving Player in the Cannabis Space

Blueberries Medical Corp. (CSE: BBM) has pre-registered 134 exclusive Colombian cannabis strains with high contents of CBD and THC.

Part of these strains have been tested by the Company’s master grower in different climates, altitudes and regions of Colombia.

The Company has an ongoing collaboration agreement with the National University for the stabilization, evaluation and development of its cannabis strains.

This gives Blueberries tremendous flexibility to set its production facilities to produce the products in highest demand by its clients with relative ease.

And the sales and distribution agreements Blueberries already has in place provide a degree of certainty, including its partnership with a key player in Europe to distribute and sell the Company’s products. In addition to the existing arrangements, Blueberries is investigating several other international relationships.

In order to develop an international distribution network, Blueberries is making progress with some potential partners located in countries where there are legal frameworks for medicinal cannabis already existing.

Madre Terra is one of the Company’s strategic partners for distribution and sale of cannabis products in Europe.

In addition, Blueberries Medical Corp. (CSE: BBM) also has a strategic partnership with Marketing Worldwide to develop, manufacture, distribute and sell Blueberries’ products (CBD-THC) in diverse countries.

This partnership will develop a platform to cover the Colombian and international markets.

Marketing Worldwide (MWW) has an extensive international distribution network in more than 70 countries across all five continents.

MWW´s extensive production department includes more than 100 national and international products sold via infomercials, commercials and catalogs.

Blueberries’ combination of exclusive cannabis strains and ongoing distribution agreements have helped the Company move closer to achieving its goal of becoming a leading international supplier of medicinal quality cannabis products.

The Blueberries Medical Leadership Team Has Extensive Knowledge and Proprietary Experience to Help Drive Success

Blueberries Medical Corp. (CSE: BBM) is led by an experienced team of executives composed of a multidisciplinary and talented group of professionals with extensive experience developing international business as well as specialists in different key areas.

The Blueberries Medical Corp. team has extensive knowledge and proprietary expertise in the areas of agriculture, genetics, extraction, medicine, pharmacology and marketing.

Christian Toro – Chief Executive Officer

Christian Toro brings over 40 years of experience to the Blueberries Medical Corp. executive team. This extensive experience provides Blueberries the capability to bring customized products to the market. Mr. Toro began his professional career at Publicidad Toro in 1978, a leading Colombian marketing and advertising firm, and was appointed Chief Executive Officer in 1982. Mr. Toro is also the founder of Manning Selvage & Lee (a public relations firm) and Arena (a media buying company). Mr. Toro has worked in advertising and marketing for the National Coffee Growers Association in Colombia for more than 25 years.

Camilo Villalba – Chief Operating Officer

Mr. Villalba was a founding partner in 2016 of Optim Holdings, a consulting firm focused on natural resources to assist companies in the development of investment projects along the value chain in the oil & gas and mining industries. Mr. Villalba has considerable experience in oil and gas project evaluations, financial planning, project structuring, promotion and execution of mineral exploration and oil trading operations.

Andres Castañeda – Country Manager

Mr. Castañeda is the Country Manager and Co-Founder of Blueberries SAS and has experience in managing blueberry cultivation in the Bogota savanna, as one of the pioneers in the region. Mr. Castañeda also has 12 years of international accounting experience leading the finance, logistics and marketing functions for various entities, and has experience in Canada and the Bahamas.

Miguel Cervantes – Master Grower 

Mr. Cervantes has twelve years of self-cultivation experience and genetics development.

Cannabis specialist with studies focused on medicinal and cosmetic use of cannabis at the National University of Colombia.

Andres Vidal

Mr. Vidal has over 19 years of general experience in the pharmaceutical sector with over seven years of experience relating specifically to marketing in the pharmaceutical industry. This extensive experience allows the company to develop its distribution strategy of specific formulations to the pharmacies and medical community. Mr. Vidal has been involved with product development and the registration of certain medicines before Colombian governmental authorities. Mr. Vidal obtained a Medical Doctorate (2002) and Master’s Degree in Pharmacology (2008) from the Universidad Nacional de Colombia.

As you can see…Blueberries Medical Corp. (CSE: BBM) offers investors a high upside opportunity thanks to its position as an early leader in the Colombian cannabis space.

The combination of the company’s present valuation…along with its low-cost advantage and ideal production location, extensive cultivation, product development, medical and marketing expertise, make this an investment with high upside potential.

Investors looking for the next growth opportunity in the cannabis space should consider investing in Blueberries Medical Corp. (CSE: BBM) before this undervalued company sees a potential spike in share price.

1 https://www.cbc.ca/news/world/canada-colombia-cannabis-investment-canopy-narcos-1.4819766
2 https://www.statista.com/statistics/369076/gross-domestic-product-gdp-growth-rate-in-colombia/
3 http://www.worldbank.org/en/news/feature/2016/01/14/colombia-winning-the-war-on-poverty-and-inequality-despite-the-odds
4 https://www.grandviewresearch.com/press-release/global-medical-marijuana-market

Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This is a Native Advertisement, meaning it is an informational paid marketing piece. MarijuanaStox.com makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Please review all investment decisions with a licensed investment advisor. This Advertorial was paid for by Blueberries Medical Corp. in an effort to enhance public awareness of Blueberries Medical Corp. and its securities. Winning Media has or expects to receive up to one hundred twenty thousand dollars by Blueberries Medical Corp. as a total production budget for this advertising effort. Neither MarijuanaStox.com or Winning Media currently holds the securities of Blueberries Medical Corp. and does not currently intend to purchase such securities. This Advertorial contains forward-looking statements that involve risks and uncertainties. This Advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured Company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s)” “anticipate(s)”, “plan(s)” “expect(s)” “project(s)” “will” “make” “told” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cau se actual events or actual results of the Company to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company, or contained in this advertorial are not guarantees of future performance, and that the Issuer’s actual results may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various factors including, but not limited to, the Company’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this advertorial contains “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this advertorial may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating certain actions “may,” “could,” or “might” occur. More information on the Company may be found at www.sec.gov readers can review all public filings by the Company at the SEC’s EDGAR page. MarijuanaStox.com is not a certified financial analyst or licensed in the securities industry in any manner. The information in this Advertorial is subjective opinion and may not be complete, accurate or current and was paid for, so this could create a conflict of interest.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Autism can be Treated with Medical Pot in Minnesota
02 December 2017
Florida is About to Offer a Medical Marijuana Drive-Thru
19 June 2018
Largest Pot Growing Operation Was Just Discovered
12 July 2017